Glenmede Trust’s Merck MRK Stock Holding History

Glenmede Trust’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-68	Closed	-$23K	–	1237
2020 Q4	$23K	Buy	+68	New	+$5.2K	﹤0.01%	1149

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Glenmede Trust's MRK Position: Q2 2026 in Review

Glenmede Trust reduced its Merck (MRK) stake by 25% in Q2 2026, selling an estimated $15.3M and leaving 391,031 shares worth $50.2M. The position accounts for 0.22% of the portfolio, ranked #87.

Glenmede Trust first reported a position in MRK in Q2 2013 and has held it in 51 quarters since. The position peaked at $237M in Q2 2017. 3,833 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Glenmede Trust held 391,031 shares of Merck worth $50.2M as of Q2 2026.
Glenmede Trust sold 130,347 Merck shares in Q2 2026, an estimated $15.3M.
Merck made up 0.22% of Glenmede Trust's portfolio in Q2 2026, its #87 holding.
Glenmede Trust first reported a position in Merck in Q2 2013 and has held it in 51 quarters since.
Glenmede Trust's Merck position peaked at $237M in Q2 2017.
3,833 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.